| 0.055 0.001 (1.66%) | 04-25 11:46 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.07 | 1-year : | 0.08 |
| Resists | First : | 0.06 | Second : | 0.07 |
| Pivot price | 0.05 |
|||
| Supports | First : | 0.05 | Second : | 0.04 |
| MAs | MA(5) : | 0.05  |
MA(20) : | 0.05 |
| MA(100) : | 0.05 |
MA(250) : | 1.04 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 20.9 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 11.14 | Low : | 0.02 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BLPH ] has closed above bottom band by 45.2%. Bollinger Bands are 31.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.06 - 0.06 | 0.06 - 0.06 |
| Low: | 0.05 - 0.05 | 0.05 - 0.05 |
| Close: | 0.05 - 0.06 | 0.06 - 0.06 |
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Mon, 22 Apr 2024
Bellerophon Therapeutics (NASDAQ:BLPH) Receives New Coverage from Analysts at StockNews.com - Defense World
Sun, 21 Apr 2024
Bellerophon Therapeutics (BLPH) Stock Sinks As Market Gains: What You Should Know - Yahoo Movies UK
Mon, 04 Mar 2024
Bellerophon Shareholders Vote to Dissolve Amid Board Resignations - TipRanks.com - TipRanks
Tue, 25 Jul 2023
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today? - InvestorPlace
Mon, 05 Jun 2023
Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today? - InvestorPlace
Fri, 27 Jan 2023
7 Micro-Cap Stocks to Buy for Risk-Taking Investors - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 12 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 10.4 (%) |
| Shares Short | 90 (K) |
| Shares Short P.Month | 124 (K) |
| EPS | -0.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.3 |
| Profit Margin | -164.1 % |
| Operating Margin | -195.8 % |
| Return on Assets (ttm) | -78.5 % |
| Return on Equity (ttm) | -166 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.46 |
| EBITDA (p.s.) | -0.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.18 |
| Price to Sales | 0.11 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|